Analysis of the env V3 sequences obtained from patients with HIV type 1 infection treated with the immune modulant agent tucaresolBULGHERONI, Elisabetta; BANDERA, Alessandra; GALLI, Massimo et al.AIDS research and human retroviruses. 2005, Vol 21, Num 9, pp 815-819, issn 0889-2229, 5 p.Article

Marked enhancement of the antigen-specific immune response by combining plasmid DNA-based immunization with a Schiff base-forming drugCHARO, Jehad; SUNDBÄCK, Maria; WASSERMAN, Ken et al.Infection and immunity. 2002, Vol 70, Num 12, pp 6652-6657, issn 0019-9567, 6 p.Article

The pharmacokinetics, tolerability and pharmacodynamics of tucaresol (589C80 ; 4[2-formyl-3-hydroxyphenoxymethyl] benzoic acid), a potential anti-sickling agent, following oral administration to healthy subjectsROLAN, P. E; PARKER, J. E; GRAY, S. J et al.British journal of clinical pharmacology. 1993, Vol 35, Num 4, pp 419-425, issn 0306-5251Article

Pharmacokinetics and pharmacodynamics of tucaresol, an antisickling agent, in healthy volunteersROLAN, P. E; MERCER, A. J; WOOTTON, R et al.British journal of clinical pharmacology. 1995, Vol 39, Num 4, pp 375-380, issn 0306-5251Article

Therapeutic potentiation of the immune system by costimulatory Schiff-base-forming drugsRHODES, J; CHEN, H; HALL, S. R et al.Nature (London). 1995, Vol 377, Num 6544, pp 71-75, issn 0028-0836Article

Schiff base forming drugs : mechanisms of immune potentiation and therapeutic potentialCHEN, H; RHODES, J.Journal of molecular medicine (Berlin. Print). 1996, Vol 74, Num 9, pp 497-504, issn 0946-2716Article

Tucaresol increases oxygen affinity and reduces haemolysis in subjects with sickle cell anaemiaARYA, R; ROLAN, P. E; WOOTTON, R et al.British journal of haematology. 1996, Vol 93, Num 4, pp 817-821, issn 0007-1048Article